Peter Magnusson, K. Karason
Aug 5, 2021
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Lakartidningen
Abstract
Mavacamten, a selective inhibitor of cardiac myosin ATPase, which reduces hypercontractility, is the first disease-specific treatement of HCM. In phase 2 trials including persons with HCM without outflow obstruction, a significant reduction in NT-proBNP and troponin I was reported. In the EXPLORER-HCM trial participants with hypertrophic cardiomyopathy with outflow obstruction randomized to mavacamten displayed a significant recuduction in the outflow gradient, a greater exercise capacity and an improvement in quality of life as compared with those who were randomized to placebo. Mavacamten may be of groundbreaking importance for the treatment of HCM.